These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33599720)

  • 1. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.
    Reinisch W; Sandborn WJ; Danese S; Hébuterne X; Kłopocka M; Tarabar D; Vaňásek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hoy M; Goetsch M; Bliss C; Gupta C; Cataldi F; Vermeire S
    J Crohns Colitis; 2021 Jun; 15(6):938-949. PubMed ID: 33599720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Pharmacodynamics of Ontamalimab (SHP647), a Fully Human Monoclonal Antibody Against Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1), in Patients With Ulcerative Colitis or Crohn's Disease.
    Wang Y; Marier JF; Lavigne J; Kassir N; Martin P
    J Clin Pharmacol; 2020 Jul; 60(7):903-914. PubMed ID: 32119128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study.
    D'Haens GR; Reinisch W; Lee SD; Tarabar D; Louis E; Kłopocka M; Klaus J; Schreiber S; Il Park D; Hébuterne X; Nagy P; Cataldi F; Martin SW; Nayak S; Banerjee A; Gorelick KJ; Sandborn WJ
    Inflamm Bowel Dis; 2022 Jul; 28(7):1034-1044. PubMed ID: 34427633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
    Vermeire S; Danese S; Sandborn WJ; Schreiber S; Hanauer S; D'Haens G; Nagy P; Thakur M; Bliss C; Cataldi F; Goetsch M; Gorelick KJ; Reinisch W
    J Crohns Colitis; 2024 May; 18(5):708-719. PubMed ID: 38096402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-MADCAM therapy for ulcerative colitis.
    Picardo S; Panaccione R
    Expert Opin Biol Ther; 2020 Apr; 20(4):437-442. PubMed ID: 31709847
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
    Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
    J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etrolizumab for induction of remission in ulcerative colitis.
    Rosenfeld G; Parker CE; MacDonald JK; Bressler B
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011661. PubMed ID: 26630451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis.
    Vermeire S; Lukáš M; Magro F; Adsul S; Lindner D; Rosario M; Roth J; Danese S
    J Crohns Colitis; 2020 Sep; 14(8):1066-1073. PubMed ID: 32060515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
    Sandborn WJ; Cyrille M; Hansen MB; Feagan BG; Loftus EV; Rogler G; Vermeire S; Cruz ML; Yang J; Boedigheimer MJ; Abuqayyas L; Evangelista CM; Sullivan BA; Reinisch W
    Gastroenterology; 2019 Mar; 156(4):946-957.e18. PubMed ID: 30472236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
    Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
    J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    Schulze LL; Becker E; Dedden M; Liu LJ; van Passen C; Mohamed-Abdou M; Müller TM; Wiendl M; Ullrich KAM; Atreya I; Leppkes M; Ekici AB; Kirchner P; Stürzl M; Sexton D; Palliser D; Atreya R; Siegmund B; ; Neurath MF; Zundler S
    J Crohns Colitis; 2023 Nov; 17(11):1817-1832. PubMed ID: 37208197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of vedolizumab for inflammatory bowel disease.
    Loftus EV; Feagan BG; Panaccione R; Colombel JF; Sandborn WJ; Sands BE; Danese S; D'Haens G; Rubin DT; Shafran I; Parfionovas A; Rogers R; Lirio RA; Vermeire S
    Aliment Pharmacol Ther; 2020 Oct; 52(8):1353-1365. PubMed ID: 32876349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations.
    Van den Berghe N; Verstockt B; Gils A; Sabino J; Ferrante M; Vermeire S; Declerck P; Thomas D
    J Crohns Colitis; 2021 Jun; 15(6):988-993. PubMed ID: 33245363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis.
    Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR
    Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
    Sandborn WJ; Lee SD; Tarabar D; Louis E; Klopocka M; Klaus J; Reinisch W; Hébuterne X; Park DI; Schreiber S; Nayak S; Ahmad A; Banerjee A; Brown LS; Cataldi F; Gorelick KJ; Cheng JB; Hassan-Zahraee M; Clare R; D'Haens GR
    Gut; 2018 Oct; 67(10):1824-1835. PubMed ID: 28982740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Golimumab Trough Levels at Week 6 Are Associated With Poor Clinical, Endoscopic and Histological Outcomes in Ulcerative Colitis Patients: Pharmacokinetic and Pharmacodynamic Sub-analysis of the Evolution Study.
    Magro F; Lopes S; Silva M; Coelho R; Portela F; Branquinho D; Correia L; Fernandes S; Cravo M; Caldeira P; Sousa HT; Patita M; Lago P; Ramos J; Afonso J; Redondo I; Machado P; Cornillie F; Lopes J; Carneiro F;
    J Crohns Colitis; 2019 Oct; 13(11):1387-1393. PubMed ID: 30989180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Atreya R; Peyrin-Biroulet L; Klymenko A; Augustyn M; Bakulin I; Slankamenac D; Miheller P; Gasbarrini A; Hébuterne X; Arnesson K; Knittel T; Kowalski J; Neurath MF; Sandborn WJ; Reinisch W;
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1063-1075. PubMed ID: 33031757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases Centers.
    Tursi A; Allegretta L; Buccianti N; Della Valle N; Elisei W; Forti G; Faggiani R; Gallina S; Hadad Y; Larussa T; Lauria A; Luzza F; Lorenzetti R; Mocci G; Penna A; Polimeni N; Pranzo G; Ricciardelli C; Zampaletta C; Picchio M
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):239-244. PubMed ID: 28922435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.